Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sparing carbapenem usage

Sparing carbapenem usage AbstractBackgroundCarbapenem resistance in Gram-negative bacteria is increasing in many countries and use of carbapenems and antibiotics to which resistance is linked should be reduced to slow its emergence. There are no directly equivalent antibiotics and the alternatives are less well supported by clinical trials. The few new agents are expensive.ObjectivesTo provide guidance on strategies to reduce carbapenem usage.MethodsA literature review was performed as described in the BSAC/HIS/BIA/IPS Joint Working Party on Multiresistant Gram-negative Infection Report.ResultsOlder agents remain active against some of the pathogens, although expectations of broad-spectrum cover for empirical treatment have risen. Education, expert advice on treatment and antimicrobial stewardship can produce significant reductions in use.ConclusionsMore agents may need to be introduced onto the antibiotic formulary of the hospital, despite the poor quality of scientific studies in some cases. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Antimicrobial Chemotherapy Oxford University Press

Loading next page...
 
/lp/oxford-university-press/sparing-carbapenem-usage-uuMVe25txY

References (73)

Publisher
Oxford University Press
Copyright
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
ISSN
0305-7453
eISSN
1460-2091
DOI
10.1093/jac/dkx181
pmid
28637307
Publisher site
See Article on Publisher Site

Abstract

AbstractBackgroundCarbapenem resistance in Gram-negative bacteria is increasing in many countries and use of carbapenems and antibiotics to which resistance is linked should be reduced to slow its emergence. There are no directly equivalent antibiotics and the alternatives are less well supported by clinical trials. The few new agents are expensive.ObjectivesTo provide guidance on strategies to reduce carbapenem usage.MethodsA literature review was performed as described in the BSAC/HIS/BIA/IPS Joint Working Party on Multiresistant Gram-negative Infection Report.ResultsOlder agents remain active against some of the pathogens, although expectations of broad-spectrum cover for empirical treatment have risen. Education, expert advice on treatment and antimicrobial stewardship can produce significant reductions in use.ConclusionsMore agents may need to be introduced onto the antibiotic formulary of the hospital, despite the poor quality of scientific studies in some cases.

Journal

Journal of Antimicrobial ChemotherapyOxford University Press

Published: Sep 1, 2017

There are no references for this article.